Success and Complications
In our study, the successful rate was 97.22%.
This result was equivalent to other authors: in the
study of Nguyen Lan Hieu (2013) [3], the success
rate was 94.76% ; Arora et al(2002) [6]: 95%; Butera
et al(2007) [7]: 96%; Zuo et al (2010) [9] 97.6%.
There was a failure in our study. A male patient
with the 10.17 mm-diameter muscular VSD was
unsuccessfully implanted with 16/14 ADO1, after
that we used the muscular VSD 16 to perform
the VSD closure. In ventriculography, we found
a residual shunt. After dicussion, we decided to
release the device. However, a day later, the patient
got a new Right bundle branch block (RBBB), then
ventricular arrhythmia (stabilised with lidocain).
24 hours later, he got hematuria and lasting within
1 month. On cardiac echography, we found the
flow of residual shunt became much stronger and
the function of the heart went down. So the patient
was sent to open heart operation.
In our study, there was no death or complete
AV block. Meanwhile, in other studies, complete
AV block was a concerning issue, since a lot of
patients had to have pace-makers implanted. In
Nguyen Lan Hieu’s study, the rate of pace-maker
implantation was 0.36% [3]; Arora et al(2002) [6]:
2.2%; Butera et al(2007) [7]: 5.7%; Zuo et al (2010)
[9] 1%. In the study of Predescu (2008), 20 patients
were performed with transcatheter VSD closure
successfully (100%). All patients were followed up,
and the average follow-up period was 23.1 month,
with the result that there was 20% of them must be
implanted permanent pace-makers.
6 trang |
Chia sẻ: hachi492 | Lượt xem: 13 | Lượt tải: 0
Bạn đang xem nội dung tài liệu Transcatheter closure of perimembranous and muscular ventricular septal defects: Short - Term and Mid - Term outcomes, để tải tài liệu về máy bạn click vào nút DOWNLOAD ở trên
Hue Central Hospital
Journal of Clinical Medicine - No. 62/2020 3
TRANSCATHETER CLOSURE OF PERIMEMBRANOUS
AND MUSCULAR VENTRICULAR SEPTAL DEFECTS:
SHORT - TERM AND MID - TERM OUTCOMES
Ho Anh Binh1, Le Van Duy1, Nguyen Ngoc Minh Châu1
DOI: 10.38103/jcmhch.2020.62.1
ABSTRACT
Objective: This study attempted to report the initial results: the safety and efficacy of transcatheter closure
of ventricular septal defects (VSDs) at Hue Central Hospital with the short and medium-term follow-up.
Methods: From September 2012 to May 2017, a total of 36 patients with perimembranous or muscular
VSD underwent an attempt of transcatheter closure at the Department of Interventional Cardiology, Hue
Central Hospital.
Results: 14 males and 26 females participated in this study, with the age of 17.29 ± 13.72 and
24.23 ± 12.32 respectively. Among these patients, 19.44% of them were under 6-year-old; 72.22% had
perimembranous VSDs, 27.78% had muscular VSDs, and 33.33% had aneurysm. The distance to AV was
5.62 ± 4.32 mm. The device size was 15.31± 8.12 mm. Procedures lasted for 57.17 ± 26.5 min with 15.31±
8.12 min of exposure. The complete closure rates by transthoracic echocardiography after 24 hours, 1
month, 3 months and 6 months (transthoracic) were 94.44%; 94.44% ; 97.22% and 100%, respectively.
Mean time of follow-up was 11.92 ± 8.36 (3-38) months. Success rate was 97.22% and no death occurred.
There was 1 case of hematuria, lasting 1 month; no Atrioventricular (AV) block.
Conclusions: Transcatheter closure of VSDs is a novel, feasible and safe technique with high success
rate (97.22%). The transcather approach provides a less invasive alternative than surgical closure and
might become the first choice treatment in selected patients.
Key words: transcatheter closure, ventricular septal defects
1. Hue Central Hospital Corresponding author: Ho Anh Binh
Email: drhoanhbinh@gmail.com
Received: 8/5/2020; Revised: 17/5/2020
Accepted: 20/6/2020
I. INTRODUCTION
The simple VSD, which accounts for 25% of
congenital heart disease (CHD) in children, is the
most common CHD. Besides, VSD is also com-
mon in other CHD as Fallot, with atrial septal de-
fect [1]. 70-80% of small VSDs close spontaneously
by late childhood; only 10-15% of large VSDs can
close spontaneously. About 60% of defects close
before age 3 and 90% before age 9. The risk factors
for decreased survival in unoperated patients include:
cardiomegaly on chest X - ray, elevated systolic pulmo-
nary artery pressure (PAPS) (>50 mmHg) and cardio-
vascular symptoms. Therefore, before these patients
got elevated PAPS, VSD closure should be taken by
surgical or transcatheter closure. The first time that
transcatheter VSD closure has been undertaken was
Bệnh viện Trung ương Huế
4 Journal of Clinical Medicine - No. 62/2020
Transcatheter closure of perimembranous...
in 1988 by Lock et al [2].
In Vietnam, from 2003, National Heart Institute of
Vietnam reported the first case of transcatheter VSD
closure [3]. Until now, other congenital heart centers
such as The City Children’s Hospital and Medicine
University Hospital at Ho Chi Minh City [4] have
undertaken this procedure routinely with impressive
results.
At Hue City, thanks to the help from experts of
National Heart Institute of Vietnam, we performed the
first transcatheter VSD closure in September 2012,
and after that the technique has been taken routinely
since 2013. However, since this is an advance
technique, which has just applied in our hospital,
we would like to study “Transcatheter closure of
perimembranous and muscular ventricular septal
defects: short and medium-term outcome” with aims:
the feasibility and safety of the technique according
to the short and medium-term results of transcatheter
VSD closure at Hue Central Hospital.
II. MATERIALS AND METHODS
2.1. Participants
The study was conducted as a prospective, non-
randomized and interventional registry involving
36 patients with perimemberanous or muscular
VSDs, hospitalized at the Interventional Cardi-
ology Department of Hue Central Hospital from
9/2012 to 5/2017.
2.2. Eligibility criteria [1,5]
Patients with the following characteristics were
eligible for device closure:
- Patients with perimemberanous or muscular
VSDs.
- The symptomatic patients showing a Qp/Qs >
1.5:1.
- PAPS >50 mmHg.
- Increased left ventricular and left atrial size, or
deteriorating left ventricular function in the absence
of irreversible pulmonary hypertension.
- Presence of a perimembranous or outlet VSD
with mild-to-severe aortic regurgitation.
- History of recurrent endocarditis.
- In children, a nonrestrictive VSD and a smaller
VSD with significant symptoms failing to respond
to pharmacotherapy.
2.3. Exclusion criteria [1,5]
- Weight less than 3 kg.
- Distance between the VSD and the aortic,
pulmonic, mitral or tricuspid valves less than 4 mm.
- Pulmonary vascular resistance greater than 7
Woods units.
- Sepsis/ Active bacterial infections.
- Contraindications to antiplatelet therapy.
Before intervention, an informed written
consent was obtained from all parents of
participants. Physical examination, blood tests, a
chest X-ray, standard 12-lead electrocardiogram
(ECG), and transthoracic echocardiogram (TTE)
were routinely performed in all patients.
A team including cardiologists, cardiac surgeons
and interventional cardiologists decided to perform
the transcatheter VSD closure or not.
2.4. Device implantation
- The catheterization procedure was performed
under general anaesthesia for children and local
anaesthesia for adults.
- Access: femoral vien and femoral artery.
- Full heart catheterization.
- Ventriculography to diagnose the position,
size, characteristics and number of VSDs, then
the devices to peform the VSD closure could be
decided.
- IM or JR catheter with 260 wire, and snare to
do an arteriovenous circuit through the femoral vein
approach.
- A delivery system (6 to 12 Fr) was advanced
to the left ventricle through the arteriovenous
circuit. Through the delivery system, an occluder
was deployed under fluoroscopic control.
- Before the release of the occluders, ventricu-
lography and aortography were performed again to
Hue Central Hospital
Journal of Clinical Medicine - No. 62/2020 5
verify complete occlusion of the VSD and to iden-
tify any new-onset aortic valve regurgitation.
- After the procedure, patients were transferred
to the cardiac wards. One day later, cardiac echog-
raphies were done. Aspirin (5 mg/kg daily) was
administered for 6 months in all patients.
2.5. Evaluation
- Sucess: the occluders were in the right positions,
no residual shunt or minor residual shunt occurred.
- Failure: the procedures could not be completed,
and changed to surgical closures because of device
embolization or major residual shunt.
- Complications: blood loss requiring
transfusion, device embolization, new onset
valvular regurgitation requiring surgical repair,
atrioventricular block requiring pacemaker
implantation or death.
2.6. Data analysis: using Excel, SPSS.
III. RESULTS
A total of 36 patients with perimembranous
or muscular VSDs were analyzed.
Mean age significantly differed between men
and women (p<0.05) (Table 1). Table 2 showed
the cardiac catheterization and ventriculography.
Table 3 presented the procedural data. Among 36
procedures: 1 ADO II implanted; 1 Muscular VSD
implanted and 34 ADO I implanted (Table 4).
Regarding adverse events (Table 5): Complete VSD
closure procedures: 100%; Sucess rate: 97.22%;
Follow-up (months): 11.92 ± 8.36 (3-38).
Table 1: Patients
Patient Male Female Total
n 14 (38.89%) 22 (61.11%) 36 (100%)
Mean age 17.29± 13.72 24.23± 12.32 21.50± 16.27
Youngest 1 year-old
Oldest 59 year-old
< 6 year old 7 (19.44%)
Table 2: Cardiac catherization and ventriculography
VSD characteristics
Position Perimembranous 26 (72.22%)
Muscular 10 (27.78%)
Aneurysm 12 (33.33%)
Distance to AV (mm) 5.62 ± 4.32 (2.5- 26)
PAPs (mmHg) 28.61 ± 2.19
Gradient (LV/RV) mmHg 81.63 ± 8.35
EF (%) 63.74 ± 3.36
VSD diameter Echo catheterization
LV side (mm) 6.40 ± 2.27 7.42 ± 5.45
RV side (mm) 4.70 ± 2.94 3.73 ± 0.76
Bệnh viện Trung ương Huế
6 Journal of Clinical Medicine - No. 62/2020
Transcatheter closure of perimembranous...
IV. DISCUSSION
In our study, the youngest patient was only
1-year-old, and under 6-year-old patients was
19.44%. This result was equivalent with other
studies such as the study of Nguyen Lan Hieu [3]
and Truong Quang Binh.
There were some old patients in our study, the
oldest was 59 year-old. The mean age in the study
was 17.29 ± 13.72 in males and 24.23 ± 12.32 in
females (p<0.05). In Nguyen Lan Hieu’s study,
the patients’ mean age was 12.75 ± 11.09 and in
the study of Mario Carminatil, Gianfranco Butera
et al [5], the patients’ mean age was 8-year-old.
The patients’ mean age in both studies was younger
compared to our participants (p<0.05). In our study,
the patients were identified as having VSD rather
late, since some of them didn’t care to their health
problem. Others, especially female patients, had
not hospitalized after founding VSDs because
of psychological fator (scare) or high medical
treatment cost. Therefore, we had to perform the
transcatheter VSD closure in late stage.
4.1. VSD characteristics
In our study, most of VSDs were perimembranous
(72.22%), while only 27.78% of VSDs were
muscular (p<0.05).
In the study of Mario Carminatil, Gianfranco
Butera et al [5], there were 58.14% perimembranous
VSDs, 27.67% muscular VSDs, 3.72% multi VSDs
and 10.47% residual VSDs after surgical closures.
Meanwhile, Nguyen Lan Hieu [3] chose 100%
perimembranous VSDs for transcatheter VSD
clossure in his study.
In our study, the mean distance from VSDs
to aortic valves was 5.62 ± 4.32 mm. There was
a patient, who were identified as having VSD
Table 3: Procedural data
Mean Minimum Maximum
Time of
procedure (min.) 57.17 ± 26.5 30 150
Time of exposure
(min.) 15.31 ± 8.12 6.5 31.8
Contrast (ml) 114.22 ± 40.53 60 200
Table 4: Devides used
Devices Mean Minimum Maximum
Size of Amplatzer (mm) 7.30 ± 0.52 6 16
Size of Deli (F) 9.79 ± 3.62 6 12
Table 5: Adverse events
In Cathlab 24h 1 month 3 months > 6 months
Death 0 0 0 0 0
Residual shunting 3 2 2 1 0
Hematuria 0 1 1 0 0
arrhythmia 1 1 0 0 0
AR/TR 0 0 0 0 0
Cardiac dysfunction 0 0 1 0 0
Hue Central Hospital
Journal of Clinical Medicine - No. 62/2020 7
with aneurysm, having only 2.5 mm-distance
between VSD and aortic valve. We decided to do
transcatheter closure, using a suitable device which
was implanted inside the aneurysm of the VSD so
that the rim of the device did not affect to the aortic
valve (no regurgitation). There was no residual
shunt after the VSD closure. However, this case
should be precisely treated because of the risk of
aortic valve regurgitation and heart faillure after
VSD closure. So the position of device should be
carefully evaluated by ventriculography and TTE
before releasing the device.
In this study, there was no significantly difference
in sizes of VSDs measuring by cardiac echographies
and ventriculographies (p<0.05). However, in left
ventricles, the diameters of VSDs were slightly
bigger when measuring by ventriculographies than
cardiac echographies. The results were contrary in
right ventricles.
In Nguyen Lan Hieu’s study, the mean diameter
of the VSDs on the left and right side was 7.05±
3.43 mm and 4.61±2.01 mm respectively; the mean
length of VSDs was 6.61± 3.07 mm. These data had
no significant difference with the ones in our study
(p>0.05) [3].
4.2. Technical consideration
In our study, the mean time to finish the procedures
was 57.17± 26.5 (30-150) min and the mean time of
x-ray exposures was 15.31± 8.12 min. In the study
of Mario Carminatil, Gianfranco Butera et al [5], the
average time of procedures was 120 min (30-300
min) and the average time of x-ray exposures was
33 min (4-149 min). Comparing these two study, it
was shown that we could perform the transcatheter
VSD closure more rapidly (p<0.05). However, the
average age of our participants was older; under-6-
year-old patients occupied only 19.44% while in the
study of Mario Carminatil, Gianfranco Butera et al,
the data was 42%. This was the main factor affecting
to the mean time of procedures and x-ray exposures.
In children, the procedures were performed under
general anaesthesia, and it was more difficult when
doing VSD closure in children than in aldults.
Futhermore, we only performed VSD closure in
perimembranous or muscular VSDs while Mario
Carminatil, Gianfranco Butera et al had undertaken
VSD closure in patients with perimembranous,
muscular, multi VSDs and residual VSDs after
surgical clossures. The difficult technique factors
were also objections to perform the procedures and
lengthening time to finish VSD closure.
4.3. Device implantation
In our study, 94.45% of devices were ADO I.
This device is used to perform PDA closures.
According to my opinion, this device has a disc
in the left ventricle and no disc in the right side
after implantation, so that there is no compression
to ventricle wall as the two discs device. This
advantage may help to reduce the risk of complete
AV block after implantation. There was no complete
AV block in our study. However, the reasons why
we could use ADO I were the limited number of
our patients and simple VSDs’ characteristics. In the
future, we should study in large scale patients with
long - term follow up to confirm this theory.
In Nguyen Lan Hieu’s study, he recommended
that in VSDs with aneurysm, devices with 2 discs
with slightly bigger size should be used and the
devides should be positioned inside the aneurysm.
If there was significantly difference between the left
and right ventricle size, the devices’ size should be
chosen basing on the smaller diameter of VSDs. In
some patients, we may accept minor residual shunts
rather than oversize devices that would ultimately
cause complete AV block. [3]
In several studies, based on the size and
characteristics of VSDs, some foreign authors
[5-8] had chosen many kinds of devices such as:
Membranous Amplatzer Muscular, Amplatzer
PDA, Amplatzer ASD, Amplatzer Starflex, Coil, etc
to perform VSD closure.
Bệnh viện Trung ương Huế
8 Journal of Clinical Medicine - No. 62/2020
4.4. Success and Complications
In our study, the successful rate was 97.22%.
This result was equivalent to other authors: in the
study of Nguyen Lan Hieu (2013) [3], the success
rate was 94.76% ; Arora et al(2002) [6]: 95%; Butera
et al(2007) [7]: 96%; Zuo et al (2010) [9] 97.6%.
There was a failure in our study. A male patient
with the 10.17 mm-diameter muscular VSD was
unsuccessfully implanted with 16/14 ADO1, after
that we used the muscular VSD 16 to perform
the VSD closure. In ventriculography, we found
a residual shunt. After dicussion, we decided to
release the device. However, a day later, the patient
got a new Right bundle branch block (RBBB), then
ventricular arrhythmia (stabilised with lidocain).
24 hours later, he got hematuria and lasting within
1 month. On cardiac echography, we found the
flow of residual shunt became much stronger and
the function of the heart went down. So the patient
was sent to open heart operation.
In our study, there was no death or complete
AV block. Meanwhile, in other studies, complete
AV block was a concerning issue, since a lot of
patients had to have pace-makers implanted. In
Nguyen Lan Hieu’s study, the rate of pace-maker
implantation was 0.36% [3]; Arora et al(2002) [6]:
2.2%; Butera et al(2007) [7]: 5.7%; Zuo et al (2010)
[9] 1%. In the study of Predescu (2008), 20 patients
were performed with transcatheter VSD closure
successfully (100%). All patients were followed up,
and the average follow-up period was 23.1 month,
with the result that there was 20% of them must be
implanted permanent pace-makers.
V. CONCLUSIONS
Transcatheter device closure is an effective method
in treating VSDs with high success rate (96.3%).
This is a novel, feasible and safe technique, while
adverse events were rare and generally manageable.
The transcatheter approach provides a less invasive
alternative than surgical closure and might become
the first choice treatment in selected patients.
REFERENCES
1. Trung ĐH, Thông liên thất, Bệnh học Tim mạch
tập 2. 2006: Nhà xuất bản Y học.
2. Lock J, Block P, McKay R, Baim D, Keane
JJC. Transcatheter closure of ventricular septal
defects. 1988; 78: 361 - 368.
3. Hiếu NL, Hiếu TB. Đánh giá kết quả đóng thông
liên thất phần quanh màng bằng dụng cụ bít ống
động mạch qua đường ống thông. Tạp chí Y học
thực hành 2013; 866: 135 - 138.
4. Bình TQ, Phi LT, Tín ĐN, Nga BTX, Vũ VH.
Hiệu quả bước đầu của thông tim can thiệp TLT
tại Bệnh viện Đại học Y Dược - Thành phố Hồ
Chí Minh. 2010.
5. Carminati M, Butera G, Chessa M, De Giovanni J,
Fisher G, Gewillig M, et al. Transcatheter closure
of congenital ventricular septal defects: results of
the European Registry. 2007; 28: 2361 - 2368.
6. Arora R, Trehan V, Kumar A, Kalra G, Nigam
MJJoic. Transcatheter closure of congenital
ventricular septal defects: experience with
various devices. 2003; 16: 83 - 91.
7. Butera G, Carminati M, Chessa M, Piazza L,
Micheletti A, Negura DG, et al. Transcatheter closure
of perimembranous ventricular septal defects: early
and long-term results. 2007; 50: 1189 - 1195.
8. Yang J, Yang L, Wan Y, Zuo J, Zhang J, Chen
W, et al. Transcatheter device closure of
perimembranous ventricular septal defects: mid-
term outcomes. 2010; 31: 2238 - 2245.
9. Predescu D, Chaturvedi RR, Friedberg MK,
Benson LN, Ozawa A, Lee K - JJTjot, et al.
Complete heart block associated with device
closure of perimembranous ventricular septal
defects. 2008; 136: 1223 - 1228.
Transcatheter closure of perimembranous...
Các file đính kèm theo tài liệu này:
transcatheter_closure_of_perimembranous_and_muscular_ventric.pdf